Published in Cardiovascular Business Week, September 9th, 2008
"This revised indication for moderately severe pain underscores the effectiveness of Ralivia(TM) in patients with moderate to moderately severe pain," said Biovail Chief Executive Officer Bill Wells. "Ralivia(TM) provides an analgesic option for patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.